Home › NDC Lookup › Ingredients › Avapritinib › 72064-0150-30
⚪image loading
(from DailyMed)

Ayvakit avapritinib 50 mg Tablet, Film Coated, 30-count — NDC 72064-150-30 (Billing 72064-0150-30)

by Blueprint Medicines Corporation · 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

This is a package of 30 tablets of Ayvakit avapritinib 50 mg Tablet, Film Coated from Blueprint Medicines Corporation, marketed since Jun 2021 and currently FDA-listed. It is this product's only package size.

NDC 72064-0150-30
🏷️ FDA NDC (as labeled) 72064-150-30 billing pads the product segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 72064-150-30 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
72064 labeler · 150 product · 30 package
Package marketed since
Jun 16, 2021
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 7206415030 5
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 72064-150-30
Product NDC 72064-150
11-digit billing NDC 72064015030
NCPDP billing unit EA — each (per item)
Application # NDA212608
SPL Set ID c6bf8968-b0ec-46f8-91ca-f73ff9b1f1c1
Established class (EPC) Kinase Inhibitor; Multidrug and Toxin Extrusion Transporte
Mechanism of action Bile Salt Export Pump Inhibitors; Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2C9 Inhibitors; Multidrug and Toxin Extrusion Transporter 1 Inhibitors
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-06-16
Route ORAL
Dosage form TABLET, FILM COATED
Substance AVAPRITINIB

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 082419
GCN 49826
HICL code 046291
Ingredient (HICL) Avapritinib
HIC1 code V
Therapeutic class — broad (HIC1) Neoplasms
HIC2 code V1
Therapeutic class — intermediate (HIC2) Antineoplastic Drugs
HIC3 code V1Q
Therapeutic class — specific (HIC3) Antineoplastic Systemic Enzyme Inhibitors
AHFS code 10:00.00.00
AHFS class Antineoplastic Agents
FDB label name AYVAKIT 50 MG TABLET
FDB brand name Ayvakit
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 082419
  • GCN: 49826
  • HICL (First Databank): 046291
  • AHFS class code: 10:00.00.00
Why two NDCs? The FDA registers this code as 72064-150-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 72064-0150-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name AYVAKIT 50 MG TABLET Ingredient Avapritinib
📖 What it is MedlinePlus · NLM

Avapritinib is used to treat a certain type of gastrointestinal stromal tumor (GIST; a type of tumor that grows in the wall of the stomach, intestine [bowel], or esophagus [tube that connects the throat with the stomach]) in adults that has spread to other parts of the body or that cannot be removed by surgery. It is also used to treat certain types of mastocytosis (a blood disorder in which there are too many mast cells [a certain kind of white blood cell]). Avapritinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Avapritinib treats certain adults with GIST that has a PDGFRA exon 18 mutation and can’t be removed by surgery or has spread. It also treats advanced and indolent systemic mastocyt...
  • Take it by mouth once a day on an empty stomach. That means at least 1 hour before or 2 hours after eating. If you miss a dose and your next one is within 8 hours, skip it. If you...
  • Swelling, nausea, tiredness, diarrhea, and dizziness are common. Some people notice memory or concentration problems. Tell your care team about any of these. They can often adjust...
  • Get immediate medical help for a sudden headache, vomiting, vision changes, or confusion. These can be signs of bleeding in the brain, which is rare but serious. Treatment would ne...
📖 Read our full Avapritinib guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $1,432.96 $42,988.82 / 30 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
72064-0150-30 You're viewing this Main listing 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC 2020-01-09 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ayvakit 50 mgthis 72064-0150-30 Blueprint 30 tablets — — FDA listed —
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
First FDA approval
Jan 2020
📍
2026
Currently FDA-listed
6 years listed
🛡️
2042
Latest patent/protection listed
not a guaranteed launch date
🔒No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.

🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Mar 2042. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
📅 FDA approved Jan 9, 2020 RLD RS ⏳ ~15.4 yr to latest listed protection

Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.

Patents & exclusivity — FDA Orange Book
US 9944651 — drug substance (U-2726)
US 9994575 — drug substance (U-2726)
US 9200002 — drug substance (U-2726)
US 9994575 — drug substance (U-2726)
US 9200002 — drug substance (U-2726)
US 9944651 — drug substance (U-2726)
US 9944651 — drug substance (U-2726)
US 9994575 — drug substance (U-2726)
US 9200002 — drug substance (U-2726)
US 11999744 — method of use (U-3168)
US 11999744 — method of use (U-3168)
US 11999744 — method of use (U-3168)
US 11999744 — method of use (U-3168)
US 11999744 — method of use (U-3506)
US 9200002 — drug substance (U-3168)
US 9200002 — drug substance (U-3168)
US 9200002 — drug substance (U-3168)
US 9200002 — drug substance (U-3168)
US 12060354 — method of use (U-2726)
US 12060354 — method of use (U-2726)
US 12060354 — method of use (U-2726)
US 12252494 — method of use (U-3506)
US 9944651 — drug substance (U-3168)
US 9944651 — drug substance (U-3168)
US 9944651 — drug substance (U-3168)
US 9944651 — drug substance (U-3168)
US 9994575 — drug substance (U-3168)
US 9994575 — drug substance (U-3168)
US 9994575 — drug substance (U-3168)
US 9994575 — drug substance (U-3168)
US 9944651 — drug substance (U-3506)
US 9994575 — drug substance (U-3506)
US 9200002 — drug substance (U-3506)
US 11827642 — drug substance (U-3506)
US 11964980 — drug substance
US 11964980 — drug substance
US 11964980 — drug substance
US 11964980 — drug substance
US 11964980 — drug substance
Exclusivity ODE-356
Exclusivity ODE-366
Exclusivity ODE-434
Exclusivity ODE-356
Exclusivity ODE-366
Exclusivity ODE-434
Exclusivity ODE-356
Exclusivity ODE-366
Exclusivity ODE-434
Exclusivity I-912
Exclusivity ODE-356
Exclusivity ODE-366
Exclusivity ODE-434
Exclusivity ODE-356
Exclusivity ODE-366
Exclusivity ODE-434
2020 2022 2024 2026 2028 2030 2032 2034 2036 2038 2040 2042
Today
LOE
Substance patent Formulation patent Method-of-use patent Exclusivity Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
Patent
Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
Substance patent
Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
Formulation (product) patent
Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
Method-of-use patent
A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
Skinny label
A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
Exclusivity
FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
Paragraph IV
A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
RLD / RS
Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
TE / AB rating
FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
LOE (loss of exclusivity)
The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.

Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.

Listed patents (39)
PatentTypeUse codeExpires
US 9944651 ↗ Drug substance U-2726 Oct 15, 2034
US 9994575 ↗ Drug substance U-2726 Oct 15, 2034
US 9200002 ↗ Drug substance U-2726 Oct 15, 2034
US 9994575 ↗ Drug substance U-2726 Oct 15, 2034
US 9200002 ↗ Drug substance U-2726 Oct 15, 2034
US 9944651 ↗ Drug substance U-2726 Oct 15, 2034
US 9944651 ↗ Drug substance U-2726 Oct 15, 2034
US 9994575 ↗ Drug substance U-2726 Oct 15, 2034
US 9200002 ↗ Drug substance U-2726 Oct 15, 2034
US 11999744 ↗ Method of use U-3168 Apr 10, 2040
US 11999744 ↗ Method of use U-3168 Apr 10, 2040
US 11999744 ↗ Method of use U-3168 Apr 10, 2040
US 11999744 ↗ Method of use U-3168 Apr 10, 2040
US 11999744 ↗ Method of use U-3506 Apr 10, 2040
US 9200002 ↗ Drug substance U-3168 Oct 15, 2034
US 9200002 ↗ Drug substance U-3168 Oct 15, 2034
US 9200002 ↗ Drug substance U-3168 Oct 15, 2034
US 9200002 ↗ Drug substance U-3168 Oct 15, 2034
US 12060354 ↗ Method of use U-2726 Mar 8, 2042
US 12060354 ↗ Method of use U-2726 Mar 8, 2042
US 12060354 ↗ Method of use U-2726 Mar 8, 2042
US 12252494 ↗ Method of use U-3506 Apr 10, 2040
US 9944651 ↗ Drug substance U-3168 Oct 15, 2034
US 9944651 ↗ Drug substance U-3168 Oct 15, 2034
US 9944651 ↗ Drug substance U-3168 Oct 15, 2034
US 9944651 ↗ Drug substance U-3168 Oct 15, 2034
US 9994575 ↗ Drug substance U-3168 Oct 15, 2034
US 9994575 ↗ Drug substance U-3168 Oct 15, 2034
US 9994575 ↗ Drug substance U-3168 Oct 15, 2034
US 9994575 ↗ Drug substance U-3168 Oct 15, 2034
US 9944651 ↗ Drug substance U-3506 Oct 15, 2034
US 9994575 ↗ Drug substance U-3506 Oct 15, 2034
US 9200002 ↗ Drug substance U-3506 Oct 15, 2034
US 11827642 ↗ Drug substance U-3506 Oct 15, 2034
US 11964980 ↗ Drug substance — Apr 10, 2040
US 11964980 ↗ Drug substance — Apr 10, 2040
US 11964980 ↗ Drug substance — Apr 10, 2040
US 11964980 ↗ Drug substance — Apr 10, 2040
US 11964980 ↗ Drug substance — Apr 10, 2040
FDA exclusivity
CodeWhat it grantsExpires
ODE-356Orphan Drug Exclusivity (7-year)Jun 16, 2028
ODE-366Orphan Drug Exclusivity (7-year)Jan 9, 2027
ODE-434Orphan Drug Exclusivity (7-year)May 22, 2030
ODE-356Orphan Drug Exclusivity (7-year)Jun 16, 2028
ODE-366Orphan Drug Exclusivity (7-year)Jan 9, 2027
ODE-434Orphan Drug Exclusivity (7-year)May 22, 2030
ODE-356Orphan Drug Exclusivity (7-year)Jun 16, 2028
ODE-366Orphan Drug Exclusivity (7-year)Jan 9, 2027
ODE-434Orphan Drug Exclusivity (7-year)May 22, 2030
I-912New indication (3-year)May 22, 2026
ODE-356Orphan Drug Exclusivity (7-year)Jun 16, 2028
ODE-366Orphan Drug Exclusivity (7-year)Jan 9, 2027
ODE-434Orphan Drug Exclusivity (7-year)May 22, 2030
ODE-356Orphan Drug Exclusivity (7-year)Jun 16, 2028
ODE-366Orphan Drug Exclusivity (7-year)Jan 9, 2027
ODE-434Orphan Drug Exclusivity (7-year)May 22, 2030
Common questions
Is there a generic version of AYVAKIT 50 MG TABLET?
No FDA-approved generic equivalent is currently listed in the FDA Orange Book for AYVAKIT 50 MG TABLET. Based on the patents and exclusivity currently listed, the Orange Book estimate is that full-label generic entry may be delayed until Mar 2042 — an estimate, not a guaranteed launch date.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Avapritinib inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBlueprint Medicines Corporation
Application holderBLUEPRINT MEDICINES CORP
FDA applicationNDA212608 (NDA)
Labeler code72064
First marketedJun 2021
Product typeHuman Prescription Drug
Portfolio5 products on file

More NDCs from Blueprint Medicines Corporation labeler code 72064

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ayvakit — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ayvakit. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$76.68M
Claims incl. refills
1.8K
Beneficiaries
680
Spend / beneficiary
$112,768.65
Spend / claim
$42,507.03
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Blueprint Medicines Corporation. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Blueprint Medicines Corporation is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 72064-0130-30 · Blueprint 72065-0001-01 · Xeris →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.